Update on the development of lurasidone as a treatment for patients with acute schizophrenia

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 107-115

  Yasui Furukori, Norio ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

5 HT7; Antipsychotic; BDNF; Cognition; Lurasidone; Schizophrenia

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE 2 RECEPTOR; HISTAMINE H1 RECEPTOR; LURASIDONE; MESSENGER RNA; MUSCARINIC M1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; PLACEBO; QUETIAPINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; ANTIDEPRESSANT AGENT; ISOINDOLE DERIVATIVE; N (2 (4 (1,2 BENZISOTHIAZOL 3 YL) 1 PIPERAZINYLMETHYL) 1 CYCLOHEXYLMETHYL) 2,3 BICYCLO(2.2.1)HEPTANEDICARBOXIMIDE; N-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYLMETHYL)-1-CYCLOHEXYLMETHYL)-2,3-BICYCLO(2.2.1)HEPTANEDICARBOXIMIDE; NEUROLEPTIC AGENT; SEROTONIN RECEPTOR; THIAZOLE DERIVATIVE;

ACUTE SCHIZOPHRENIA; AGITATION; AKATHISIA; ARTHRALGIA; COGNITION; COGNITIVE DEFECT; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DISEASE MODEL; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSTONIA; HIPPOCAMPUS; HUMAN; HYPERSALIVATION; METABOLOMICS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MUSCULOSKELETAL STIFFNESS; NAUSEA; NONHUMAN; PARKINSONISM; PHARMACODYNAMICS; PREFRONTAL CORTEX; RECEPTOR AFFINITY; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; STRESS; SWIMMING; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; PHYSIOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CLINICAL TRIALS AS TOPIC; COGNITION; HUMANS; ISOINDOLES; METABOLOMICS; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; THIAZOLES;

EID: 84865309699     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S11180     Document Type: Review

References (78)

1. Gold JM. Cognitive defcits as treatment targets in schizophrenia. Schizophr Res. 2004;72(1):21-28.
2. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72(1):41-51.
3. Elvevåg B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14(1):1-21.
4. Harvey PD. When does cognitive decline occur in the period prior to the frst episode of schizophrenia? Psychiatry (Edgmont). 2009;6(7):12-14.
5. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50(11):884-897. Erratum in: Biol Psychiatry. 2002;51(4):346.
6. Cannon TD, Bearden CE, Hollister JM, Rosso IM, Sanchez LE, Hadley T. Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr Bull. 2000;26:379-393.
7. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994;344:1398-1402.
8. Lencz T, Smith C, McLaughlin D, et al. Generalized and specifc neurocognitive defcits in prodromal schizophrenia. Biol Psychiatry. 2006;59:863-871.
9. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry. 2000;57:637-648.
10. Niendam TA, Bearden CE, Rosso IM, et al. A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. Am J Psychiatry. 2003;160:2060-2062.
11. Gold JM. Is cognitive impairment in schizophrenia ready for diagnostic prime time? World Psychiatry. 2008;7:32-33.
12. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science. 2002;296:692-695.
13. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood fow evidence. Arch Gen Psychiatry. 1986;43:114-124.
14. Ragland JD, Laird AR, Ranganath C, Blumenfeld RS, Gonzales SM, Glahn DC. Prefrontal activation defcits during episodic memory in schizophrenia. Am J Psychiatry. 2009;166:863-874.
15. Harvey PD. Mood symptoms, cognition, and everyday functioning: in major depression, bipolar disorder, and schizophrenia. Innov Clin Neurosci. 2011;8(10):14-18.
16. Bowie CR, Leung W W, Reichenberg A, et al. Predicting schizophrenia patients' real-world behavior with specifc neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63(5):505-511. Epub July 27, 2007.
17. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profle of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-181.
18. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18(11): 1715-1726.
19. Stahl SM. The serotonin-7 receptor as a novel therapeutic target. J Clin Psychiatry. 2010;71(11):1414-1415.
20. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-836.
21. Meltzer H Y, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placeboand olanzapinecontrolled study. Am J Psychiatry. 2011;168(9): 957-967.
22. Potkin SG, Ogasa M, Cucchiaro J, et al. Double-blind comparison of the safety and effcacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132(2-3):101-107.
23. Kane JM. Lurasidone: a clinical overview. J Clin Psychiatry. 2011;72(Suppl 1):24-28.
24. Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses. 2011;4(4):251-257.
25. Citrome L. Lurasidone for schizophrenia: a review of the effcacy and safety profle for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189-210.
26. Roberts AJ, Hedlund PB. The 5-HT(7) receptor in learning and memory. Hippocampus. April 11, 2011. [Epub ahead of print.]
27. Nikiforuk A. Selective blockade of 5-HT7 receptors facilitates attentional set-shifting in stressed and control rats. Behav Brain Res. 2012;226(1):118-123.
28. Ishiyama T, Tokuda K, Ishibashi T, et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol. 2007;572(2-3):160-170.
29. Enomoto T, Ishibashi T, Tokuda K, et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res. 2008;186(2):197-207.
30. Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition defcit in rats. J Pharmacol Exp Ther. 2011;338(2):605-614.
31. Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl). 2011;213(2-3):289-305.
32. Kazuhito Ikeda K, Murai T, Tsujimura T, et al. A unique cognitive enhancing effect of lurasidone in object retrieval with detours, a test of executive function in non-human primates. Poster presented at the 40th annual meeting of Society for Neuroscience; Nov 2010; San Diego, CA.
33. Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition defcit in rats. J Pharmacol Exp Ther. 2011;338(2):605-614.
34. 2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl). 2011;217(1):13-24.
35. Horisawa T, Ishibashi T, Nishikawa H, et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the benefcial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res. 2011;220(1):83-90.
36. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA. Intellectual defcits in frst-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull. 1992;18(3):437-448.
37. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58(2):158-164.
38. Ruhrmann S, Schultze-Lutter F, Bechdolf A, Klosterkötter J. Intervention in at-risk states for developing psychosis. Eur Arch Psychiatry Clin Neurosci. 2010;260(Suppl 2):S90-S94.
39. Kaur T, Cadenhead KS. Treatment implications of the schizophrenia prodrome. Curr Top Behav Neurosci. 2010;4:97-121.
40. Horiguchi M, Meltzer HY. Co-treatment with the atypical antipsychotic drug (APD) lurasidone, or the 5-HT1A agonist, tandospirone, prevents the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in female rats. Poster presented at Neuroscience 2011, the 41st Annual Meeting of Society for Neuroscience; Nov 2011; Washington, DC.
41. Angelucci F, Brenè S, Mathé AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry. 2005;10(4):345-352.
42. Fumagalli F, Calabrese F, Luoni A, Bolis F, Racagni G, Riva MA. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmacol. 2012;15(2):235-246.
43. Luoni A, Fumagalli F, Calabrese F, Ogasa M, Racagni G, Riva MA. Modulation of neurotrophic mechanisms after chronic treatment with the novel antipsychotic lurasidone in rat. Poster presented at the 24th European College of Neuropsychopharmacology Congress; Sep 2011; Paris, France.
44. Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Ya n Z. The novel antipsychotic drug lurasidone enhances NMDA receptor-mediated synaptic responses. Mol Pharmacol. 2012;81(2):113-119.
45. Potkin SG, Silva R, Cucchiaro J. Metabolomic correlates of response in patients with schizophrenia treated with lurasidone. Poster presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011; Honolulu, HI.
46. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010;11(7):802-812.
47. Guscott M, Bristow LJ, Hadingham K, et al. Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology. 2005;48(4): 492-502.
48. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG. 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol Psychiatry. 2005;58(10):831-837.
49. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl). 2009;206(3):345-354.
50. Hedlund PB, Cates L, Roberts AJ, Huitron-Resendiz S. The a ntidepressant-like effects of lurasidone are mediated by the 5-HT7 receptor. Poster presented at Neuroscience 2011, the 41st Annual Meeting of Society for Neuroscience; Nov 2011; Washington, DC.
51. Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011;7:239-250.
52. Owen RT. Lurasidone: a new treatment option for schizophrenia. Drugs Today (Barc). 2011;47(11):807-816.
53. Loebel A, Cucchiaro J, Sarma K, et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week, Pearl 3 trial. Poster presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011; Honolulu, HI.
54. Latuda [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; Dec 2011 Available from: http://www.latuda.com/ LatudaPrescribingInformation.pdf. Accessed December 20, 2011.
55. Stahl SM, Lonnen AJ. The mechanism of drug-induced akathsia. CNS Spectr. January 15, 2011. [Epub ahead of print.]
56. Newcomer J W, Pikalov A, Cucchiaro J, et al. Impact of lurasidone and olanzapine on Framingham ten year coronary heart disease risk estimate in schizophrenia. Presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011; Honolulu, HI.
57. Keefe RS, Bilder RM, Davis SM, et al; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64:633-647.
58. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother. 2010;10:43-57.
59. Harvey P, Siu C, Cucchiaro J, Pikalov A, Maruff P, Loebel A. Cognitive performance in patients with schizophrenia treated with lurasidone: Results from a placebo and active-controlled acute phase study followed by a 6 month double-blind extension. Poster presented at the 50th Annual Meeting of American College of Neuropsychopharmacology; Dec 2011; Waikoloa Beach, HI.
60. Green MF. What are the functional consequences of neurocognitive defcits in schizophrenia? Am J Psychiatry. 1996;153(3):321-330.
61. Bowie CR, Leung W W, Reichenberg A, et al. Predicting schizophrenia patients' real-world behavior with specifc neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63:505-551.
62. Harvey PD, Lombardi J, Leibman M, et al. Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Am J Psychiatry. 1997;154(2):205-210.
63. Kurtz MM. Symptoms versus neurocognitive skills as correlates of everyday functioning in severe mental illness. Expert Rev Neurother. 2006;6(1):47-56.
64. Velligan DI, Mahurin RK, Diamond PL, et al. The functional signifcance of symptomatology and cognitive function in schizophrenia. Schizophr Res. 1997;25(1):21-31.
65. Lencz T, Smith C W, McLaughlin D, et al. Generalized and specifc neurocognitive defcits in prodromal schizophrenia. Biol Psychiatry. 2006;59(9):863-871.
66. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol. 1997;11:123-131.
67. Goldman-Rakic PS, Muly EC 3rd, Williams G V. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 2000;31: 295-301.
68. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148: 1474-1486.
69. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44: 660-669.
70. Mnie-Filali O, Dahan L, Zimmer L, Haddjeri N. Effects of the serotonin 5-HT(7) receptor antagonist SB-269970 on the inhibition of dopamine neuronal fring induced by amphetamine. Eur J Pharmacol. 2007;570:72-76.
71. Cifariello A, Pompili A, Gasbarri A. 5-HT(7) receptors in the modulation of cognitive processes. Behav Brain Res. 2008;195(1):171-179.
72. Meneses A. 5-HT system and cognition. Neurosci Biobehav Rev. 1999;23:1111-1125.
73. Meneses A. A pharmacological analysis of an associative learning task: function of 5-HT1 to 5-HT7 receptor subtypes on a Pavlovian/ instrumental autoshaped memory. Learn Mem. 2003;10:363-372.
74. Meneses A, Manuel-Apolinar L, Rocha L, Castello E, Castello C. Expression of the 5-HT receptors in rat brain during memory consolidation. Behav Brain Res. 2004;152:425-436.
75. Bonaventure P, Nepomuceno D, Hein L, Sutcliffe JG, Lovenberg T, Hedlund PB. Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine(7) receptor distribution and uncovers 8-hydroxy-2-(di-n-propylamino)tetralin interaction with alpha(2) adrenergic receptors. Neuroscience. 2004;4:901-911.
76. Plassat JL, Amlaiky N, Hen R. Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993;2:229-236.
77. Martín-Cora FJ, Pazos A. Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. Br J Pharmacol. 2004;1:92-104.
78. Latuda [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; Dec 2011. Available from: http://www.latuda.com/ LatudaPrescribingInformation.pdf. Accessed Dec 20, 2011.